U.S. Food and Drug Administration (FDA) Commissioner, Scott Gottlieb, MD, recently announced a new pilot program to improve transparency around clinical trial information to spur innovation and scientific analysis for new drugs.

The Agency plans to continue sharing information around product approvals and improve its transparency regarding clinical study reports that may be advantageous to patients, providers and scientists. Some information on drug approvals is currently shared with the public, but according to complaints, it is done through a complex and confusing format. The FDA plans to initiate talks with drug companies to assess their willingness to participate in the program and then solicit public feedback once the pilot is completed.

Keywords: ACC Publications, Cardiology Magazine, ACC18, ACC Annual Scientific Session, Myocardial Infarction, Drug Approval, Fellowships and Scholarships, Ursidae, Goals, Social Media, Quality Improvement, Leadership, Motivation, Athletes, Inpatients, Rural Population, Blood Pressure, Medicaid, Outpatients, Pilot Projects, Arrhythmias, Cardiac, Medicare, Patient Care, Percutaneous Coronary Intervention, Electronic Health Records, Electrocardiography, Coronary Artery Bypass, Awards and Prizes, Consumer Product Safety, Heart Failure, Running, Defibrillators, Heart Valves, Heart Valve Diseases, Pacemaker, Artificial, Cardiopulmonary Resuscitation, Cohort Studies

< Back to Listings